Comparison
Cagrilintide vs. Semax
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
1415456-99-3
80714-61-0
Molecular weight
4253.7 g/mol
813.92 g/mol
Half-life
168 h
0.3 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYMet-Glu-His-Phe-Pro-Gly-ProMechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
4
of which in humans
3
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
1